Rebiotix Clinical, Microbiome Data from First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018
New data continues to underscore company leadership in microbiome field
Download this press release (241 KB).
ROSEVILLE, MN – OCTOBER 01, 2018 — Rebiotix Inc., part of the Ferring Pharmaceuticals Group, announced today that data new from their Microbiota Restoration Therapy™ (MRT) drug development platform will be presented at the annual Infectious Disease conference, which will be held October 3-7 in San Francisco.
Each data set highlights the company’s continued leadership in the microbiome field, providing new insight into the durability of RBX2660 months after use as treatment in their recent Open-Label trial, to be presented by Rebiotix’s Associate Director of Clinical Research, Sarah Mische, PhD. Additionally, the company will share findings from the novel application of their Microbiome Health Index™, which has been developed as platform to quantify changes in patient microbiome profiles; Rebiotix’s Chief Scientific Officer, Ken Blount, PhD, will present the latest developments.
The schedule of poster presentations is as follows: